We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Eylea HD improved vision with extended dosing intervals ...
The U.S. Food and Drug Administration has accepted for Priority Review Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) ...
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program highlight durability of visual improvements and consistent safety across extended dosing intervals and patient ...
BAYRY posts in-line Q4 earnings but revenues miss on lower Xarelto and Eylea sales. 2026 sales guidance signals steady growth ...
Credit: Regeneron. Eylea HD is supplied as a sterile, aqueous solution for intravitreal injection in a single-dose vial containing 8mg of aflibercept. The Food and Drug Administration (FDA) has ...
Regeneron Pharmaceuticals REGN put up a decent performance for the fourth quarter of 2025 and full-year 2025 (reported last month) with overall revenues rising despite a continued decline in sales of ...
(Reuters) -Regeneron Pharmaceuticals Inc's first-quarter sales of blockbuster eye drug Eylea came in below Wall Street targets on Thursday as competition heated up, dragging the company's shares more ...
Add Yahoo as a preferred source to see more of our stories on Google. Feb 17 (Reuters) - Ocular Therapeutix said on Tuesday its experimental eye disease drug was more effective in helping patients ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Eylea for the treatment of retinopathy of prematurity in preterm infants, according to a press ...
New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated ...
On June 2, 2025, the Patent Trial and Appeal Board (“Board”) issued decisions denying institution of Samsung Bioepis’s IPR2025-00176 and Formycon’s IPR2025-00233 against claims 1–12, 14–17, 19, 20, 22 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results